BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31176960)

  • 21. Cost of skeletal complications from bone metastases in six European countries.
    Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
    J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canadian health care institution resource utilization resulting from skeletal-related events.
    Habib MJ; Merali T; Mills A; Uon V
    Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The burden of skeletal-related events in patients with prostate cancer and bone metastasis.
    Roghmann F; Antczak C; McKay RR; Choueiri T; Hu JC; Kibel AS; Kim SP; Kowalczyk KJ; Menon M; Nguyen PL; Saad F; Sammon JD; Schmid M; Sukumar S; Sun M; Noldus J; Trinh QD
    Urol Oncol; 2015 Jan; 33(1):17.e9-17.e18. PubMed ID: 25443265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
    Bhowmik D; Song X; Intorcia M; Gray S; Shi N
    Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.
    Katakami N; Kunikane H; Takeda K; Takayama K; Sawa T; Saito H; Harada M; Yokota S; Ando K; Saito Y; Yokota I; Ohashi Y; Eguchi K
    J Thorac Oncol; 2014 Feb; 9(2):231-8. PubMed ID: 24419421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
    Hagiwara M; Delea TE; Chung K
    J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost of treating skeletal-related events in patients with prostate cancer.
    Lage MJ; Barber BL; Harrison DJ; Jun S
    Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
    Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
    Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients.
    Zhong Y; Valderrama A; Yao J; Donga P; Bilir P; Neumann PJ
    Value Health; 2018 Mar; 21(3):304-309. PubMed ID: 29566837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skeletal-related events due to bone metastases from differentiated thyroid cancer.
    Farooki A; Leung V; Tala H; Tuttle RM
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2433-9. PubMed ID: 22564664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
    Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
    J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark.
    Svendsen ML; Gammelager H; Sværke C; Yong M; Chia VM; Christiansen CF; Fryzek JP
    Clin Epidemiol; 2013; 5():97-103. PubMed ID: 23576882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006.
    Sathiakumar N; Delzell E; Morrisey MA; Falkson C; Yong M; Chia V; Blackburn J; Arora T; Brill I; Kilgore ML
    Breast Cancer Res Treat; 2012 Jan; 131(1):231-8. PubMed ID: 21842243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
    JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.
    Harding JJ; Abu-Zeinah G; Chou JF; Owen DH; Ly M; Lowery MA; Capanu M; Do R; Kemeny NE; O'Reilly EM; Saltz LB; Abou-Alfa GK
    J Natl Compr Canc Netw; 2018 Jan; 16(1):50-58. PubMed ID: 29295881
    [No Abstract]   [Full Text] [Related]  

  • 40. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.